Literature DB >> 15770365

Suppression of experimental aortic aneurysms: comparison of inducible nitric oxide synthase and cyclooxygenase inhibitors.

Peter J Armstrong1, David P Franklin, David J Carey, James R Elmore.   

Abstract

The rat model of abdominal aortic aneurysm (AAA) is associated with inflammation, destruction of extracellular matrix, and production of both inducible nitric oxide synthase (iNOS) and matrix metalloproteinase-9 (MMP-9). Indomethacin, a nonselective cyclooxygenase inhibitor, may prevent AAA formation by inhibiting cyclooxygenase-2 (COX-2) activity. We hypothesized that indomethacin, rofecoxib (selective COX-2 inhibitor), and 1400 W (selective iNOS activity inhibitor) would decrease aneurysm formation in the rat model. Forty-six male Wistar rats underwent intraaortic elastase infusion in two parallel studies based on medication delivery route. Sixteen rats were randomized to rofecoxib or water by gastric lavage. Thirty rats were randomized to subcutaneous saline, indomethacin, or 1400 W. Heart rate, blood pressure and aortic diameters were measured. Western Blot and mRNA analysis for MMP-9 and iNOS was performed on postoperative day 7 aortic segments. Elastin degradation and inflammation were evaluated by immunohistochemistry. Elastase infusion produced AAA in all rats. 1400 W significantly limited aneurysm expansion (p = 0.01) whereas treatment with indomethacin and rofecoxib did not. Only 1400 W significantly increased blood pressure (p < 0.001). Indomethacin alone statistically decreased MMP-9 (p < 0.011). 1400 W resulted in greater conservation of aortic elastin than indomethacin (p = 0.025). All groups demonstrated statistically similar expression of iNOS. In conclusion, selective iNOS activity inhibitor, 1400 W, significantly decreased aneurysm size and preserved aortic elastin without altering MMP-9 levels. Indomethacin significantly decreased MMP-9 expression without decreasing aneurysm size. Rofecoxib did not significantly decrease MMP-9 expression or aneurysm size. Inhibition of iNOS limits aneurysmal expansion by mechanisms other than MMP-9 inhibition. MMP-9 inhibition by indomethacin is not sufficient to limit aneurysm expansion in our model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15770365     DOI: 10.1007/s10016-004-0174-7

Source DB:  PubMed          Journal:  Ann Vasc Surg        ISSN: 0890-5096            Impact factor:   1.466


  8 in total

Review 1.  Monocytes and macrophages in abdominal aortic aneurysm.

Authors:  Juliette Raffort; Fabien Lareyre; Marc Clément; Réda Hassen-Khodja; Giulia Chinetti; Ziad Mallat
Journal:  Nat Rev Cardiol       Date:  2017-04-13       Impact factor: 32.419

2.  Nitric oxide induces the progression of abdominal aortic aneurysms through the matrix metalloproteinase inducer EMMPRIN.

Authors:  Tania R Lizarbe; Carlos Tarín; Mónica Gómez; Begoña Lavin; Enrique Aracil; Luis M Orte; Carlos Zaragoza
Journal:  Am J Pathol       Date:  2009-09-24       Impact factor: 4.307

Review 3.  Role of matrix metalloproteinase inhibitors in preventing abdominal aortic aneurysm.

Authors:  Faisal Aziz; Helena Kuivaniemi
Journal:  Ann Vasc Surg       Date:  2007-05       Impact factor: 1.466

4.  Smooth muscle cells from abdominal aortic aneurysms are unique and can independently and synergistically degrade insoluble elastin.

Authors:  Nathan Airhart; Bernard H Brownstein; J Perren Cobb; William Schierding; Batool Arif; Terri L Ennis; Robert W Thompson; John A Curci
Journal:  J Vasc Surg       Date:  2013-09-27       Impact factor: 4.268

Review 5.  Turning back the clock: regression of abdominal aortic aneurysms via pharmacotherapy.

Authors:  Hiroki Aoki; Koichi Yoshimura; Masunori Matsuzaki
Journal:  J Mol Med (Berl)       Date:  2007-05-24       Impact factor: 4.599

6.  A selective antagonist of prostaglandin E receptor subtype 4 attenuates abdominal aortic aneurysm.

Authors:  Al Mamun; Utako Yokoyama; Junichi Saito; Satoko Ito; Taro Hiromi; Masanari Umemura; Takayuki Fujita; Shota Yasuda; Tomoyuki Minami; Motohiko Goda; Keiji Uchida; Shinichi Suzuki; Munetaka Masuda; Yoshihiro Ishikawa
Journal:  Physiol Rep       Date:  2018-09

Review 7.  Nonsteroidal Anti-Inflammatory Drugs: A Potential Pharmacological Treatment for Intracranial Aneurysm.

Authors:  Courtney L Fisher; Stacie L Demel
Journal:  Cerebrovasc Dis Extra       Date:  2019-04-30

8.  SMAD3 deficiency promotes inflammatory aortic aneurysms in angiotensin II-infused mice via activation of iNOS.

Authors:  Chek K Tan; Eddie H Tan; Baiwen Luo; Charlotte L Huang; Joachim S Loo; Cleo Choong; Nguan S Tan
Journal:  J Am Heart Assoc       Date:  2013-06-19       Impact factor: 5.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.